Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-Stage Kidney Failure Patients
This study is ongoing, but not recruiting participants.
Study NCT00426712   Information provided by Dynavax Technologies Corporation
First Received: January 23, 2007   Last Updated: January 22, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis B
Additional conditions recognized in this trial
Hepatitis
Kidney Failure
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Kidney Diseases
Liver Diseases
Renal Insufficiency
Urologic Diseases
Virus Diseases
Interventions listed in this trial
Hepatitis B Vaccine (Recombinant)
Sponsors listed in this trial
Dynavax Technologies Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services